Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by dollarhunteron Jul 06, 2004 12:28pm

103 Views

Post# 7678501

RE: Great news

As well this phase1 in the US will also include MRI imaging to track the patient's tumor decline. If I'm not mistaken. I think SS suggested this might happen a while back. Good call SS. This is a very positive step for Exherin and Adherex. "This will be the first clinical study of Exherin(TM) in the U.S. In addition to further exploring the tolerability and pharmacokinetics of the drug, the clinical study will use Dynamic-MRI imaging techniques to assess the time-course of activity of Exherin(TM) on a patient's tumor and its blood supply. The study is expected to begin in July and will enroll up to 20 patients." We are only going up from here people so hold on!!! Regards, DH

Bullboard Posts

New Pacific Metals delivers robust Silver Sand pre-feasibility study